Resveratrol Nanoparticle Encapsulation for Targeted Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of resveratrol (RSV) lack efficient delivery methods to target specific sites in the body, leading to suboptimal bioavailability and potential side effects, limiting its therapeutic efficacy for diseases such as diabetes, cancer, and cardiovascular diseases.
Innovation Solution
Encapsulating RSV with a gum arabic shell and a polyvinyl alcohol coating to form nanoparticles with a size of 195-210 nm and a 1:5:5 RSV:gum arabic:polyvinyl alcohol ratio, enhancing targeted delivery and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If resveratrol is administered in conventional formulations, then it can provide therapeutic effects, but bioavailability is suboptimal and side effects occur
Solution Approach 1:
The patent divides resveratrol into nanoparticle-sized segments (195-210 nm), which dramatically increases the surface area for absorption and improves bioavailability while maintaining therapeutic efficacy. The segmentation allows the substance to be absorbed more efficiently by the body.
Solution Approach 2:
The patent creates a composite nanoparticle structure with resveratrol core, gum arabic shell, and polyvinyl alcohol coating. This composite formulation enhances bioavailability through improved solubility and stability, while the specific composition ratio (1:5:5) optimizes both therapeutic effect and safety profile.
2Reliability
If resveratrol is delivered to target sites, then therapeutic efficacy improves, but delivery efficiency is insufficient
Solution Approach 1:
The patent imparts local quality to the nanoparticle formulation by using gum arabic and polyvinyl alcohol coatings that provide targeted delivery characteristics. The surface properties of the nanoparticles are optimized to enable specific binding to target sites, improving both delivery efficiency and therapeutic efficacy simultaneously.
3Quantity of substance
If nanoparticle size is reduced to 195-210 nm, then bioavailability increases, but manufacturing precision requirements increase
Solution Approach 1:
The patent optimizes the parameter of nanoparticle size to a specific range (195-210 nm) that balances bioavailability enhancement with manufacturability. The polydispersity index is controlled within 0.195-0.225, indicating monodispersity, which ensures consistent performance while remaining achievable through standard nanofabrication techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The encapsulated RSV nanoparticles effectively increase Bcl-2 immunoreactivity, reduce apoptosis, and enhance CAR gene expression, providing therapeutic benefits for diseases like Alzheimer's, cancer, diabetes, and cardiovascular diseases.
Implementation Method 1
encapsulating RSV with a gum arabic shell and a polyvinyl alcohol coating to form nanoparticles
Implementation Method 2
a polyvinyl alcohol coating over the gum arabic shell
Implementation Method 3
The encapsulated RSV nanoparticles effectively increase Bcl-2 immunoreactivity, reduce apoptosis
Implementation Method 4
enhance CAR gene expression, providing therapeutic benefits for diseases like Alzheimer's, cancer, diabetes, and cardiovascular diseases
Data Source
AI summary
Encapsulated resveratrol (RSV) nanoparticles having a resveratrol core, a gum arabic shell, and a polyvinyl alcohol coating over the gum arabic shell. In an embodiment, an RSV:gum arabic:polyvinyl alcohol (PVA) ratio in the encapsulated nanoparticles is about 1:5:5 (w/w/w). The encapsulated RSV nanoparticles can have an average size ranging from about 195 nm to about 210 nm.